The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
A correction has been published: N Engl J Med 2002;346(18):1424.

Correspondence
PreviousPrevious
Volume 346:456-457 February 7, 2002 Number 6
NextNext

Spironolactone and ACE Inhibition in Chronic Renal Failure

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
-PubMed Citation
To the Editor: I am surprised that the authors of the letter entitled "Spironolactone in Addition to ACE Inhibition to Reduce Proteinuria in Patients with Chronic Renal Disease" (Sept. 20 issue)1 concluded that the reduction in proteinuria seen after the administration of 25 mg of spironolactone per day "could not be explained by an effect of blood pressure, since there was no significant difference in blood pressure before and after the administration of spironolactone."

In each of their eight patients, the mean blood pressure (calculated as systolic pressure + [0.67 x diastolic pressure]) was lower after treatment than before treatment, . . . [Full Text of this Article]

References



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.